 Amryt Pharma PLC LON:AMYT, NASDAQ:AMYT said the European Union regulator will now begin the formal review process for its potential treatment for a rare genetic skin disorder with no currently approved treatment. The European Medicines Agency EMA has validated the marketing authorization application for the companys Oleogel-S10 for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa in young children and adults. 